Business
Grant of Options
Grant of Options.
About this update from Theracryf Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0150V\n Evgen Pharma PLC\n 08 December 2021\n \n \n \n \n Evgen Pharma plc\n \n \n (\"Evgen\" or the \"Company\")\n \n \n \n \n \n Grant of Options \n \n \n Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that, on 8 December 2021, certain employees and directors of the Company, including the following Persons Discharging Managerial Responsibility (\"PDMR\"), were granted nil cost options (the \"Options\") over a total of 4,302,975 ordinary shares in the Company exercisable, subject to the Options vesting, for a period of up to 10 years from the date of grant and governed by the rules of the Evgen Pharma plc Long Term Incentive Plan (\"LTIP\"). \n \n \n \n \n \n \n \n \n PDMR\n \n \n \n \n Position \n \n \n \n \n Options granted \n \n \n \n \n \n \n Dr Huw Jones\n \n \n \n \n Chief Executive Officer \n \n \n \n \n 1,670,886\n \n \n \n \n \n \n Richard Moulson\n \n \n \n \n Chief Financial Officer\n \n \n \n \n 552,911\n \n \n \n \n \n \n Dr Glen Clack\n \n \n \n \n Chief Medical Officer\n \n \n \n \n 632,911\n \n \n \n \n \n \n Dr Helen Kuhlman\n \n \n \n \n Chief Business Officer\n \n \n \n \n 708,861\n \n \n \n \n \n \n Nick Mallard\n \n \n \n \n Vice President, Project Leadership\n \n \n \n \n 612,089\n \n \n \n \n \n \n \n \n The Options will vest on the third anniversary of grant based on performance against challenging strategic corporate objectives over three years (40%), share price growth (30%) and on an elapsed time basis at 3 years (30%). \n \n \n \n \n \n Following this award there are 9,786,980 options in issue, representing 3.56% of the Company's issued share capital.\n \n \n \n \n \n Enquiries:\n \n \n \n \n \n \n Evgen Pharma\n \n plc \n \n \n www.evgen.com\n \n \n \n \n \n \n \n \n via Walbrook\n \n \n \n \n \n \n \n \n Barry Clare, Chairman \n \n \n \n \n \n \n \n \n \n \n \n \n \n Richard Moulson, CFO \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n finnCap \n \n \n \n www.finncap.com\n \n \n \n \n \n \n \n +44 (0)20 7220 0500\n \n \n \n \n \n \n Geoff Nash / Teddy Whiley (Corporate Finance) \n \n \n \n \n \n \n \n \n \n \n \n \n \n Alice Lane (ECM) \n \n...